Impax Laboratories Inc. (IPXL)
-NasdaqGS 18.42 
0.22(1.18%) May 17, 4:00PM EDT|After Hours
:
18.42 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 18.64 |
|---|
| Open: | 18.67 |
|---|
| Bid: | 18.12 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 18.35 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 31-Jul-13 |
|---|
| Day's Range: | 18.18 - 18.92 |
|---|
| 52wk Range: | 14.41 - 27.25 |
|---|
| Volume: | 1,958,601 |
|---|
| Avg Vol (3m): | 1,222,180 |
|---|
| Market Cap: | 1.23B |
|---|
| P/E (ttm): | 8.43 |
|---|
| EPS (ttm): | 2.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Impax Labs launches generic version of ZomigAP(Fri, May 17)
- Impax commenced shipment of authorized generic Zomigtheflyonthewall.com(Fri, May 17)
- InPlay: Impax Labs launches authorized generic of Zomig (zolmitriptan) tablets and orally disintegrating tablets in the U.S.Briefing.com(Fri, May 17)
- Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.Business Wire(Fri, May 17)
- IMPAX LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 15)
- What Companies Will This FDA Decision Impact?at Wall St. Cheat Sheet(Mon, May 13)
- FDA allows generic forms of Endo Health's Opana ER painkillerat Reuters(Fri, May 10)
- Endo Loses Bid to Stop Sales of Generic Painkiller Rivalsat Bloomberg(Fri, May 10)
- IMPAX LABORATORIES INC FinancialsEDGAR Online Financials(Fri, May 10)
- Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire(Fri, May 10)
- 5 Big Bets Revealed By Long/Short Equity Hedge Fund Apex Capitalat Seeking Alpha(Thu, May 9)
- Endo Health turns 1Q profit, affirms 2013 forecastAP(Tue, May 7)
- 3 Healthcare Stock Earnings Snapshotsat Wall St. Cheat Sheet(Sat, May 4)
- Shire Beats Earnings in 1QZacks(Fri, May 3)
- Higher Success Rates than Small-Molecule Drugs for Antibodies: Antibodies Display More Predictable Pharmacology and More Predictable Toxicity ProfilesWall Street Transcript(Fri, May 3)
Key Statistics
| Forward P/E (1 yr): | 31.76 |
|---|
| P/S (ttm): | 2.06 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.24 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.05 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | 4.99 |
|---|
Business Summary
Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products.
View More